Who are Marker Therapeutics, Inc.'s main suppliers?

Marker Therapeutics, Inc. (MRKR) key suppliers include: CELL-READY-LLC, WILSON-WOLF-MANUFACTURING-CORPORATION. View the full supplier network at chainsifter.com/chain/MRKR.

Who are Marker Therapeutics, Inc.'s major customers?

Marker Therapeutics, Inc. (MRKR) key customers include: TScan Therapeutics, Inc., CO-LLC. View the full customer network at chainsifter.com/chain/MRKR.

What sector is Marker Therapeutics, Inc. in?

Marker Therapeutics, Inc. (MRKR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Marker Therapeutics, Inc. (MRKR) Suppliers & Customers

2Suppliers

2Customers

3Debt Items

12Related Chains

Source-Backed Evidence Depth

Marker Therapeutics, Inc. (MRKR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

8Total relationships

1Distinct source URLs

6High confidence

0.843Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Marker Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CELL-READY-LLC	CELL-READY-LLC	90%	During the three months ended March 31, 2025, the Company incurred $ 0.6 million in expenses related to services and manufacturing costs and paid $ 2.6 million for invoices received.
WILSON-WOLF-MANUFACTURING-CORPORATION	WILSON-WOLF-MANUFACTURING-CORPORATION	90%	During the three months ended March 31, 2025, the Company incurred approximately $ 29,000 in expenses related to cell culture devices and paid Wilson Wolf approximately $ 29,000 for invoices received.

Marker Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
TCRX	TScan Therapeutics, Inc.	72%	Reciprocal relationship from TCRX graph: ding transposase enzyme, which is derived from sfR fall armyworm, to deliver our TCRs into the genome of T cells. Our transposon/transposase system effectivel…
CO-LLC	CO-LLC	62%	in patients with metastatic pancreatic cancer (the “CPRIT Pancreatic Grant”). The following table summarizes grant income recorded for the three months ended March 31, 2026 and 2025, by grant: …

Marker Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
MRKR-DEBT-11068	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2016-12-31.
MRKR-DEBT-11067	Warrants outstanding: 716819	90%	xbrl warrant detail from xbrl 2020-12-31.
MRKR-DEBT	Debt stack $77,421	90%	Market cache reports total debt of $77,421.

Marker Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Marker Therapeutics, Inc..

Marker Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
MRKR-OWNER-NEA-MANAGEMENT-COMPANY-LLC	NEA Management Company, LLC	90%	13F overlay lists NEA Management Company, LLC as top holder; 36 tracked holders.

Marker Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
MYGN	Myriad Genetics, Inc.	100.00	2
NVSEF	Novartis AG	100.00	2
ALLO	Allogene Therapeutics, Inc.	50.00	2
IPSC	Century Therapeutics, Inc.	50.00	2
AUTL	Autolus Therapeutics plc	50.00	2
IOVA	Iovance Biotherapeutics, Inc.	50.00	2
LYEL	Lyell Immunopharma, Inc.	50.00	2
LEGN	Legend Biotech Corporation	50.00	2
REGN	Regeneron Pharmaceuticals, Inc.	50.00	2
TCRX	TScan Therapeutics, Inc.	36.29	1	['customer']
AMGN	Amgen Inc.	24.13	2
AMGEN	AMGEN	24.13	2

Marker Therapeutics, Inc. Supply Chain